Form 4: Pliant Therapeutics Director Receives Stock Option Grant

Director Steve E. Krognes was granted 70,000 stock options in Pliant Therapeutics as part of standard equity compensation.

Summary

• Director Steve E. Krognes received a grant of 70,000 stock options on June 11, 2026.
• The options have an exercise price of $1.14 per share.
• The options are set to expire on June 11, 2036.
• Vesting occurs in quarterly installments starting October 1, 2026, through the one-year anniversary of the grant or the next annual meeting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Potential for future dilution if options are exercised.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a standard disclosure of director equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard compensation packages for mid-cap and small-cap biotechnology firms.
• Vesting schedules tied to service periods are typical for maintaining director retention.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options beginning October 1, 2026.

Key Dates

Keywords

PLRX, Pliant Therapeutics, Form 4, Insider Trading, Stock Options, Director Compensation